BerGenBio and Oncoinvent - Key Dates for Completion of Merger

Bergen, Norway and Oslo, Norway, 24 October 2025 - Reference is made to the joint stock exchange announcement on 30 June 2025 by BerGenBio ASA (OSE: BGBIO) ("BerGenBio") and Oncoinvent ASA (OSE: ONCIN) ("Oncoinvent") regarding the combination of the two companies through a statutory triangular merger (the "Merger"), and the announcements on 4 August 2025 regarding the approval of the merger plan by the extraordinary general meetings of BerGenBio and Oncoinvent, respectively. It is currently expected that completion of the Merger will occur on 29 October 2025. Key dates and information for the completion of the Merger will then be as follows:

+--------------+-------------------------------------------------------------+ |Last day of |29 October 2025 | |trading in | | |Oncoinvent on | | |Euronext | | |Growth Oslo | | |(and last day | | |of trading | | |including | | |right to | | |merger | | |consideration)| | +--------------+-------------------------------------------------------------+ |Effective date|29 October 2025 (after close of trade) | |for completion| | |of the Merger | | +--------------+-------------------------------------------------------------+ |First day of |30 October 2025 | |trading in the| | |combined | | |company on the| | |Oslo Stock | | |Exchange | | +--------------+-------------------------------------------------------------+ |Record date |31 October 2025 | |for delivery | | |of | | |consideration | | |shares to | | |former | | |Oncoinvent | | |shareholders | | +--------------+-------------------------------------------------------------+ |Delivery of |3 November 2025 | |consideration | | |shares to | | |former | | |Oncoinvent | | |shareholders | | +--------------+-------------------------------------------------------------+ |ISIN |NO 0013251173 | |(BerGenBio, | | |unchanged) | | +--------------+-------------------------------------------------------------+ |Transferor |Oncoinvent | |company | | +--------------+-------------------------------------------------------------+ |Transferee |BerGenBio Norge AS, with consideration shares issued by | |company |BerGenBio | +--------------+-------------------------------------------------------------+ |Merger |For each Oncoinvent share held per the record date, the | |consideration |Oncoinvent shareholders will receive 1.202680493545220 shares| | |in BerGenBio, rounded down to the nearest whole share. | +--------------+-------------------------------------------------------------+ |Date of |4 August 2025 (extraordinary general meetings) | |approvals | | +--------------+-------------------------------------------------------------+ |Oncoinvent to |Effective from 28 October 2025 | |change its | | |ticker to | | |"ONCOI" | | +--------------+-------------------------------------------------------------+

In connection with the Merger, BerGenBio will change its company name to "Oncoinvent ASA" and continue its listing on the Oslo Stock Exchange under the ticker "ONCIN". The name change is expected to become effective prior to the commencement of trading on 30 October 2025. To facilitate for the continued use of the ticker "ONCIN" by the combined company following completion of the Merger, Oncoinvent will change its ticker to "ONCOI" with effect from 28 October 2025.

The Merger consideration will be settled through the issuance of a total of 117,554,012 shares in BerGenBio (the "Consideration Shares"). Any Consideration Share not delivered to the former shareholders of Oncoinvent due to rounding down shall be issued and delivered to DNB Carnegie, a part of DNB Bank ASA, who will sell the excess Consideration Shares and give the sale proceeds to BerGenBio. Following the issuance of the Consideration Shares, the share capital of BerGenBio will be NOK 156,641,128, divided into 156,641,128 shares, each with a nominal value of NOK 1. Further information on the Merger will be included in a Prospectus that is expected to be published on 28 October 2025. For further queries, please contact: Øystein Soug, Chief Executive Officer Email: soug@oncoinvent.com Tore Kvam, Chief Financial Officer, Oncoinvent ASA Email: kvam@oncoinvent.com Rune Skeie, Chief Financial Officer, BerGenBio ASA Email: rune.skeie@bergenbio.com This information is subject to the disclosure requirements pursuant to Section 5 -12 of the Norwegian Securities Trading Act. About Oncoinvent Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting micro-metastases post-surgery, harnessing the benefits of modern radiopharmaceuticals without the complexities of biological targeting. Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical development program in two indications. One Phase 1 trial and one Phase 1/2a trial have been completed and one randomized Phase 2 trial is currently ongoing in the US, UK and Europe. Early clinical efficacy data are highly encouraging, and no serious toxicity or safety concerns have been reported to date. The Oncoinvent team consists of approx. 40 employees and runs a state-of-the-art manufacturing facility to produce drug products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on the Euronext Growth Oslo. Forward-Looking Statement: All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Oncoinvent's plans, estimates, or expectations will be achieved. These forward -looking statements represent Oncoinvent's expectations as of the date of this press release, and Oncoinvent disclaims any obligation to update the forward -looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers.